|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 9/20 | |
| A61K 38/26 | |||
| A61K 31/195 | |||
| A61P 3/04 | |||
| A61P 3/10 |
| (11) | Patento numeris | 3326620 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 17204363.0 |
| Europos patento paraiškos padavimo data | 2011-12-16 | |
| (97) | Europos patento paraiškos paskelbimo data | 2018-05-30 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2020-03-04 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 10195285 | 2010-12-16 | EP | |
| 201061425087 P | 2010-12-20 | US |
| (72) |
BJERREGAARD, Simon, DK
SAUERBERG, Per, DK
Seier, NIELSEN, Flemming, DK
|
| (73) |
Novo Nordisk A/S,
Novo Allé, 2880 Bagsvęrd,
DK
|
| (54) | SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID |
| SOLID COMPOSITIONS COMPRISING A GLP-1 AGONIST AND A SALT OF N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLIC ACID |